US20230241197A1 - Protein molecule useful for anti-pseudomonas aeruginosa vaccine - Google Patents
Protein molecule useful for anti-pseudomonas aeruginosa vaccine Download PDFInfo
- Publication number
- US20230241197A1 US20230241197A1 US17/927,199 US202117927199A US2023241197A1 US 20230241197 A1 US20230241197 A1 US 20230241197A1 US 202117927199 A US202117927199 A US 202117927199A US 2023241197 A1 US2023241197 A1 US 2023241197A1
- Authority
- US
- United States
- Prior art keywords
- antigen
- amino acid
- protein
- present
- protein molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 147
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 135
- 229960005486 vaccine Drugs 0.000 title claims abstract description 32
- 239000000427 antigen Substances 0.000 claims abstract description 82
- 102000036639 antigens Human genes 0.000 claims abstract description 80
- 108091007433 antigens Proteins 0.000 claims abstract description 80
- 101710082714 Exotoxin A Proteins 0.000 claims abstract description 56
- 108010025813 Pseudomonas antigen V Proteins 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 42
- 108091033319 polynucleotide Proteins 0.000 claims description 34
- 102000040430 polynucleotide Human genes 0.000 claims description 34
- 239000002157 polynucleotide Substances 0.000 claims description 34
- 125000000539 amino acid group Chemical group 0.000 claims description 24
- 108091026890 Coding region Proteins 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 208000032536 Pseudomonas Infections Diseases 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 description 124
- 125000003275 alpha amino acid group Chemical group 0.000 description 111
- 238000006467 substitution reaction Methods 0.000 description 21
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- -1 PA14 Proteins 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 239000013598 vector Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241001098565 Pseudomonas aeruginosa PA103 Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 108010069584 Type III Secretion Systems Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 3
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 208000005333 pulmonary edema Diseases 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101150026476 PAO1 gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101100540159 Candida albicans (strain SC5314 / ATCC MYA-2876) TFP1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001133637 Homo sapiens Phosphofurin acidic cluster sorting protein 2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000276569 Oryzias latipes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100034077 Phosphofurin acidic cluster sorting protein 2 Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101100316793 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VMA1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 108010008681 Type II Secretion Systems Proteins 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- RYRIMPODRHVEIW-UHFFFAOYSA-N n-(2-phenylethyl)nitramide Chemical compound [O-][N+](=O)NCCC1=CC=CC=C1 RYRIMPODRHVEIW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Definitions
- the present invention relates to a protein molecule that is effective for an anti- Pseudomonas aeruginosa vaccine, or the like.
- Patent Literature 1 discloses immunotherapy using PcrV, a constituent of the type III secretion system.
- Patent Literature 2 discloses that a fusion protein of OprF and OprI, which is an outer membrane component protein, is effective as an anti- Pseudomonas aeruginosa vaccine.
- An object of the present invention is to provide a protein molecule effective for an anti- Pseudomonas aeruginosa vaccine.
- the present inventor came to focus on factors that seem to be unrelated to each other, namely PcrV, a component of the type III secretion system, OprF, an outer membrane component protein, and Exotoxin A, an exotoxin secreted by the type II secretion system.
- PcrV a component of the type III secretion system
- OprF an outer membrane component protein
- Exotoxin A an exotoxin secreted by the type II secretion system.
- the inventor conducted extensive research and found that excellent anti- Pseudomonas aeruginosa vaccine effects can be obtained by combining a PcrV antigen with at least one member selected from the group consisting of an OprF antigen and an Exotoxin A antigen.
- the inventor conducted further extensive research based on the above finding, and accomplished the present invention.
- the present invention includes the following aspects.
- Item 1 A protein molecule comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.
- Item 2. The protein molecule according to Item 1, wherein the domains are linked individually via a linker.
- Item 3 The protein molecule according to Item 1 or 2, comprising the PcrV antigen domain, OprF antigen domain, and Exotoxin A antigen domain.
- Item 4. The protein molecule according to Item 3, wherein the PcrV antigen domain, OprF antigen domain, and Exotoxin A antigen domain are arranged in this order.
- Item 5. The protein molecule according to any one of Items 1 to 4, which is a fusion protein.
- Item 7. A polynucleotide comprising a coding sequence of the protein molecule according to Item 5 or 6.
- Item 8. A composition comprising at least one member selected from the group consisting of a PcrV antigen and a polynucleotide comprising a PcrV antigen-coding sequence, and at least one member selected from the group consisting of an OprF antigen, a polynucleotide comprising an OprF antigen-coding sequence, an Exotoxin A antigen, and a polynucleotide comprising an Exotoxin A antigen-coding sequence.
- a drug comprising at least one member selected from the group consisting of the protein molecule according to any one of Items 1 to 6, the polynucleotide according to Item 7, and the composition according to Item 8.
- Item 10 The drug according to Item 9, which is an anti- Pseudomonas aeruginosa vaccine.
- Item 11 A drug comprising an antibody against a PcrV antigen, and at least one member selected from the group consisting of an antibody against an OprF antigen and an antibody against an Exotoxin A antigen.
- Item 12 The drug according to Item 11, which is for use in the treatment of Pseudomonas aeruginosa infection.
- the present invention provides a protein molecule, a polynucleotide, and a composition, each being effective for an anti- Pseudomonas aeruginosa vaccine, a combination of antibodies effective for the treatment of Pseudomonas aeruginosa infection, etc.
- FIG. 1 shows a vector map of a vector for generation of a gene-recombinant three-antigen protein POmT.
- FIG. 2 shows a CBB-stained image of SDS-PAGE gel of a sample in each stage in the purification of the gene-recombinant three-antigen protein POmT.
- FIG. 3 shows the results of antibody titer measurement (Test Example 1).
- the horizontal axis shows samples administered as vaccines.
- the bars indicate antigen samples used for ELISA assay.
- FIG. 4 shows the mouse survival rate after pulmonary administration of Pseudomonas aeruginosa .
- the horizontal axis shows the time elapsed from the administration of Pseudomonas aeruginosa .
- the lines indicate samples administered as vaccines.
- FIG. 5 shows the quantification results of pulmonary edema in mice after pulmonary administration of Pseudomonas aeruginosa .
- the vertical axis shows pulmonary edema (the ratio of wet weight to dry weight) and the horizontal axis shows tested groups (demonstrating the sample name administered as a vaccine).
- the terms “comprising,” “containing,” and “including” include the concepts of comprising, containing, consisting essentially of, and consisting of.
- the “identity” of amino acid sequences refers to the degree to which two or more contrastable amino acid sequences match each other. Thus, the higher the degree of match between two amino acid sequences, the higher the identity or similarity of those sequences.
- the level of amino acid sequence identity is determined, for example, by using FASTA (a tool for sequence analysis) with default parameters.
- the level of amino acid sequence identity can be determined by using the BLAST algorithm by Karlin and Altschul (Karlin S, Altschul SF. Methods for assessing the statistical significance of molecular sequence features by using general scorings schemes, Proc Natl Acad Sci USA. 87: 2264-2268(1990), Karlin S, Altschul SF.
- “conservative substitution” means the substitution of an amino acid residue with an amino acid residue having a similar side chain.
- conservative substitution means the substitution between amino acid residues having a basic side chain such as lysine, arginine, or histidine is considered to be a conservative substitution.
- substitutions between other amino acid residues are also considered to be a conservative substitution: the substitution between amino acid residues having an acidic side chain such as aspartic acid or glutamic acid; the substitution between amino acid residues having an uncharged polar side chain such as glycine, asparagine, glutamine, serine, threonine, tyrosine, or cysteine; the substitution between amino acid residues having a nonpolar side chain such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or tryptophan; the substitution between amino acid residues having a ⁇ -branched side chain such as threonine, valine, or isoleucine; and the substitution between amino acid residues having an aromatic side chain such as tyrosine, phenylalanine, tryptophan, or histidine.
- an acidic side chain such as aspartic acid or glutamic acid
- polynucleotides such as DNA or RNA
- the phosphate residue (phosphate) of each nucleotide can be substituted with, for example, a chemically modified phosphate residue such as phosphorothioate (PS), methylphosphonate, or phosphorodithionate.
- PS phosphorothioate
- methylphosphonate methylphosphonate
- phosphorodithionate phosphorodithionate
- the hydroxyl group at position 2 of the ribose of each ribonucleotide may also be substituted with —OR (R represents, for example, CH 3 (2′-O-Me), CH 2 CH 2 OCH 3 (2′-O-MOE), CH 2 CH 2 NHC(NH)NH 2 , CH 2 CONHCH 3 , or CH 2 CH 2 CN).
- R represents, for example, CH 3 (2′-O-Me), CH 2 CH 2 OCH 3 (2′-O-MOE), CH 2 CH 2 NHC(NH)NH 2 , CH 2 CONHCH 3 , or CH 2 CH 2 CN.
- the base moiety pyrimidine, purine
- the polynucleotide of the present invention also includes, but is not limited to, those formed by modifying the phosphate moiety or the hydroxyl portion, for example, by biotin, an amino group, a lower alkyl amine group, or an acetyl group.
- a BNA (LNA) and the like, in which the conformation of the sugar moiety is immobilized in the N form by bridging the 2′oxygen and 4′carbon in the sugar moiety of the nucleotide, can also be used.
- the “coding sequence” is not particularly limited as long as it is a nucleotide sequence encoding an amino acid sequence of a protein.
- the present invention relates to a protein molecule (in this specification, sometimes referred to as “protein molecule of the invention”) comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains. This is explained below.
- the PcrV antigen is not particularly limited as long as it is a peptide comprising a full or partial amino acid sequence of PcrV protein.
- the PcrV antigen domain is a partial domain comprising the protein molecule of the present invention, and is a domain comprising a PcrV antigen.
- the PcrV protein is a protein constituting the type III secretion system of Pseudomonas aeruginosa , and is one of the proteins that constitute the needle tip region of the type III secretion apparatus.
- the Pseudomonas aeruginosa strain derived from the PcrV protein is not particularly limited.
- Examples of the Pseudomonas aeruginosa strain include PA103, PAO1, PA14, PACS2, PAK, C3719, VRFPA04, and the like.
- amino acid sequences of various PcrV proteins are known, or can be predicted from known amino acid sequences and based on genomic information of a strain (e.g., a known strain or a newly obtained strain), or can be identified by cloning based on known amino acid sequences.
- the amino acid sequence of the PcrV protein in Pseudomonas aeruginosa strain PA103 is the amino acid sequence represented by SEQ ID No. 1
- PAO1 is the amino acid sequence represented by SEQ ID No. 14.
- the partial amino acid sequence of the PcrV protein is not particularly limited as long as it is a contiguous amino acid sequence of sufficient length to be used as a PcrV antigen, i.e., to induce an antibody in the PcrV protein amino acid sequence.
- the number of constituent amino acid residues of the partial amino acid sequence is, for example, 12 or more.
- the number of amino acid residues is preferably 20 or more, more preferably 50 or more, even more preferably 100 or more, still more preferably 150 or more, and further preferably 200 or more.
- the partial amino acid sequence of the PcrV protein preferably includes the C-terminal region, e.g., the amino acid region 144 th to 257 th from the N-terminus of SEQ ID No. 1 or No. 14, in view of the performance of the protein molecule of the present invention, as an anti- Pseudomonas aeruginosa vaccine.
- the full or partial amino acid sequence of the PcrV protein may have an amino acid substitution, deletion, addition, insertion, and like mutation against the full or partial amino acid sequence of the wild-type PcrV protein.
- the mutation is preferably a substitution, and more preferably a conservative substitution. If the full or partial amino acid sequence of the PcrV protein has an amino acid mutation, it has, for example, at least 90%, preferably at least 95%, more preferably at least 98%, and even more preferably at least 99% identity with the full or partial amino acid sequence of the wild PcrV protein.
- the identity is preferably at least 95%, more preferably at least 98%, and even more preferably at least 99%.
- the number of amino acids mutated in (b) above is preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and still more preferably 1 to 2.
- the number of PcrV antigen domains contained in the protein molecule of the present invention is typically one, but can be two or more (e.g., 2 to 6, 2 to 4, or 2 to 3). However, from the viewpoint of suppressing the molecular weight of the protein molecule of the present invention and facilitating the preparation, administration, and metabolism after administration, the number of PcrV antigen domains is preferably small, and particularly preferably one.
- the OprF antigen is not particularly limited as long as it is a peptide comprising the full or partial amino acid sequence of the OprF protein.
- the OprF antigen domain is a partial domain constituting the protein molecule of the present invention, and is a domain comprising an OprF antigen.
- the OprF protein is a protein composing porin of the outer membrane of Pseudomonas aeruginosa.
- the Pseudomonas aeruginosa strain from which the OprF protein is derived is the same as the Pseudomonas aeruginosa strain from which the PcrV protein is derived.
- the amino acid sequences of various OprF proteins are known or can be predicted from known amino acid sequences and based on genomic information of a strain (e.g., a known strain or a newly obtained strain), or can be identified by cloning based on known amino acid sequences.
- the amino acid sequence of the OprF protein in Pseudomonas aeruginosa strains PA103 and PA01 is the amino acid sequence represented by SEQ ID No. 15, and a mature amino acid sequence thereof (e.g., an amino acid sequence from which a signal peptide sequence is removed).
- the partial amino acid sequence of the OprF protein is not particularly limited as long as it is a contiguous amino acid sequence of sufficient length to be used as an OprF antigen, i.e., to induce an antibody in the OprF protein amino acid sequence.
- the number of constituent amino acid residues of the partial amino acid sequence is, for example, 12 or more. In terms of the performance of the protein molecule of the present invention as an anti- Pseudomonas aeruginosa vaccine, the number of amino acid residues is preferably 20 or more, more preferably 50 or more, even more preferably 100 or more, and still more preferably 120 or more.
- the partial amino acid sequence of the OprF protein is preferably used as an OprF antigen, in which case, the number of amino acid residues is preferably 250 or less, more preferably 200 or less, even more preferably 170 or less, and still more preferably 160 or less.
- the partial amino acid sequence of the OprF protein preferably includes a region containing an intermediate domain, e.g., the amino acid region 198 th to 342 nd (e.g., SEQ ID No. 3) from the N-terminus of SEQ ID No. 15, in view of the performance of the protein molecule of the present invention as an anti- Pseudomonas aeruginosa vaccine.
- an intermediate domain e.g., the amino acid region 198 th to 342 nd (e.g., SEQ ID No. 3) from the N-terminus of SEQ ID No. 15, in view of the performance of the protein molecule of the present invention as an anti- Pseudomonas aeruginosa vaccine.
- the full or partial amino acid sequence of the OprF protein may have an amino acid substitution, deletion, addition, insertion, and like mutation against the full or partial amino acid sequence of the wild-type OprF protein.
- the mutation is preferably a substitution, and more preferably a conservative substitution. If the full or partial amino acid sequence of the OprF protein has an amino acid mutation, it has, for example, at least 90%, preferably at least 95%, more preferably at least 98%, and even more preferably at least 99% identity with the full or partial amino acid sequence of the wild OprF protein.
- the full or partial amino acid sequence of a wild OprF protein e.g., the amino acid sequence represented by SEQ ID No. 15, or a partial amino acid sequence thereof, or the amino acid sequence comprising the amino acid sequence represented by SEQ ID No. 3
- the amino acid sequence having at least 90% identity with the full or partial amino acid sequence of a wild OprF protein e.g., the amino acid sequence represented by SEQ ID No. 15, or a partial amino acid sequence thereof, or the amino acid sequence comprising the amino acid sequence represented by SEQ ID No. 3).
- the identity is preferably at least 95%, more preferably at least 98%, and even more preferably at least 99%.
- the number of amino acids mutated in (d) above is preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and still more preferably 1 to 2.
- the number of OprF antigen domains contained in the protein molecule of the present invention is typically one, but can be two or more (e.g., 2 to 6, 2 to 4, or 2 to 3). However, from the viewpoint of suppressing the molecular weight of the protein molecule of the present invention and facilitating the preparation, administration, and metabolism after administration, the number of OprF antigen domains is preferably small, and particularly preferably one.
- the Exotoxin A antigen is not particularly limited as long as it is a peptide comprising the full or partial amino acid sequence of Exotoxin A protein.
- the Exotoxin A antigen domain is a partial domain constituting the protein molecule of the present invention, and a domain comprising the Exotoxin A antigen.
- the Exotoxin A protein is the main cytotoxic in which Pseudomonas aeruginosa is secreted in a type II secretion mode.
- the Pseudomonas aeruginosa strain from which the Exotoxin A protein is derived is the same as the Pseudomonas aeruginosa strain from which the PcrV protein is derived.
- the amino acid sequences of various Exotoxin A proteins are known or can be predicted from known amino acid sequences and can be predicted based on genomic information of a strain (e.g., a known strain or a newly obtained strain), or can be identified by cloning based on known amino acid sequences.
- the amino acid sequence of the Exotoxin A protein in Pseudomonas aeruginosa strain PA103 is the amino acid sequence represented by SEQ ID No. 16, and mature amino acid sequence thereof (e.g., an amino acid sequence from which a signal peptide sequence is removed).
- the partial amino acid sequence of the Exotoxin A protein is not particularly limited as long as it is a contiguous amino acid sequence of sufficient length to be used as an Exotoxin A, i.e., to induce an antibody in the Exotoxin A protein amino acid sequence.
- the number of constituent amino acid residues of the partial amino acid sequence is, for example, 12 or more. In terms of the performance of the protein molecule of the present invention as an anti- Pseudomonas aeruginosa vaccine, the number of amino acid residues is preferably 20 or more, more preferably 50 or more, even more preferably 100 or more, still more preferably 150 or more, and further more preferably 200 or more.
- the partial amino acid sequence of the Exotoxin A protein is preferably used as an Exotoxin A antigen.
- the number of amino acid residues is preferably 500 or less, more preferably 400 or less, even more preferably 300 or less, and further preferably 250 or less.
- the partial amino acid sequence of the Exotoxin A protein preferably includes a region containing an enzyme active site, e.g., the amino acid region 413 rd to 638 th from the N-terminus of SEQ ID No. 16 (e.g., SEQ ID No. 5), in view of the performance of the protein molecule of the present invention, as an anti- Pseudomonas aeruginosa vaccine.
- an enzyme active site e.g., the amino acid region 413 rd to 638 th from the N-terminus of SEQ ID No. 16 (e.g., SEQ ID No. 5), in view of the performance of the protein molecule of the present invention, as an anti- Pseudomonas aeruginosa vaccine.
- the full or partial amino acid sequence of the Exotoxin A protein may have an amino acid substitution, deletion, addition, insertion, and like mutation against the full or partial amino acid sequence of the wild-type Exotoxin A protein.
- the mutation is preferably a substitution, and more preferably a conservative substitution. If the full or partial amino acid sequence of the Exotoxin A protein has an amino acid mutation, it has, for example, at least 90%, preferably at least 95%, more preferably at least 98%, and even more preferably at least 99% identity with the full or partial amino acid sequence of the wild Exotoxin A protein.
- the enzyme-active amino acid of Exotoxin A in the case of SEQ ID No. 16, the 578 th amino acid (glutamic acid) from the N-terminus) is preferably deleted. This can reduce side effects in the administration subject.
- Exotoxin A protein Preferable examples of the full or partial amino acid sequence of Exotoxin A protein include the amino acid sequences described in (e) and (f) below:
- the full or partial amino acid sequence of wild Exotoxin A protein e.g., the amino acid sequence represented by SEQ ID No. 16, or a partial amino acid sequence thereof, or the amino acid sequence comprising the amino acid sequence represented by SEQ ID No. 5
- the amino acid sequence having at least 90% identity with the full or partial amino acid sequence of wild Exotoxin A protein e.g., the amino acid sequence represented by SEQ ID No. 16, or a partial amino acid sequence thereof, or the amino acid sequence comprising the amino acid sequence represented by SEQ ID No. 5.
- the identity is preferably at least 95%, more preferably at least 98%, and even more preferably at least 99%.
- the number of mutated amino acids in (d) above is preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and still more preferably 1 to 2.
- the number of Exotoxin A antigen domains contained in the protein molecule of the present invention is typically one, but can be two or more (e.g., 2 to 6, 2 to 4, and 2 to 3). However, from the viewpoint of suppressing the molecular weight of the protein molecule of the present invention, and facilitating preparation, administration, and metabolism after administration, the number of Exotoxin A antigen domains is preferably small, and particularly preferably one.
- the domains are each directly or indirectly linked.
- the linkage may be due to peptide bonding or other chemical cross-linking (e.g., carbodiimide chemistry, reductive animation, cyanylation chemistry (e.g., CDAP chemistry), maleimide chemistry, hydrazide chemistry, ester chemistry, and N-hydroxy succinic acid imide chemistry.)
- chemical cross-linking e.g., carbodiimide chemistry, reductive animation, cyanylation chemistry (e.g., CDAP chemistry), maleimide chemistry, hydrazide chemistry, ester chemistry, and N-hydroxy succinic acid imide chemistry.
- linker When the domains are indirectly linked, they are preferably linked via a linker.
- linker include peptide linkers, chemically cross-linked linkers (e.g., linkers having 4 to 12 carbon atoms, bifunctional linkers, linkers containing one or two reactive amino groups at the end, B-proprionamido, nitrophenylethylamine, haloacyl halide, 6-aminocaproic acid, and ADH).
- Preferable examples include peptide linkers.
- the domains are each preferably linked via a linker.
- the domains are each linked via a peptide linker (i.e., the protein molecule of the present invention is a fusion protein). This allows the protein molecule of the present invention to be stably isolated and purified using genetic recombination technology, enabling achievement of high performance as an anti- Pseudomonas aeruginosa vaccine.
- the peptide linker is not particularly limited as long as it functions as a linker. It is preferable that the peptide linker is an amino acid sequence that does not foam a secondary structure, such as ⁇ -helix structure or ⁇ -sheet structure, and that it is freely foldable.
- the peptide linker is preferably an amino acid sequence consisting of units of several amino acid residues linked.
- the peptide linker is preferably a linker (GS linker) comprising glycine and serine. Specific examples include GGGGS (SEQ ID No. 17), GSG, SAGG (SEQ ID No. 18), GGGS (SEQ ID No. 19), or GGSG (SEQ ID No. 20) as a constituent unit.
- the number of amino acid residues in the peptide linker is not particularly limited, and is, for example, 3 or more, preferably 3 to 20, and more preferably 4 to 10. By keeping the number of amino acid residues in the peptide linker at this level, the molecular weight of the protein molecule of the present invention can be reduced, and the preparation, administration, and metabolism after administration can be facilitated.
- the protein molecule of the present invention in view of the performance of the protein molecule of the present invention as an anti- Pseudomonas aeruginosa vaccine, it is particularly preferred to contain three domains (PcrV antigen domain, OprF antigen domain, and Exotoxin A antigen domain).
- the PcrV antigen domain, the OprF antigen domain, and the Exotoxin A antigen domain are preferably arranged in this order.
- the protein molecule of the present invention is a fusion protein
- the PcrV antigen domain, the OprF antigen domain, and the Exotoxin A antigen domain are preferably arranged in this order from the N-terminus.
- the protein molecule of the present invention may contain amino acid sequences other than those listed above (e.g., tag sequence and other antigen domain sequences).
- the number of amino acid residues constituting the protein molecule of the present invention is preferably 1000 or less, more preferably 900 or less, even more preferably 800 or less, and particularly preferably 700 or less, from the viewpoint of facilitating preparation, administration, and metabolism after administration.
- the number of amino acid residues is preferably 400 or more, more preferably 500 or more, and even more preferably 600 or more.
- the protein molecule of the present invention may be chemically modified as long as the function as an anti- Pseudomonas aeruginosa vaccine is not greatly impaired.
- the protein molecule of the present invention may have a carboxyl group (—COOH), carboxylate (—COO ⁇ ), amide (—CONH 2 ), or ester (—COOR) at the C-terminus.
- R in the ester is, for example, a C 1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, or n-butyl; a C 3-8 cycloalkyl group such as cyclopentyl or cyclohexyl; a C 6-12 aryl group such as phenyl or ⁇ -naphthyl; a phenyl-C 1-2 alkyl group such as benzyl or phenethyl; a C 7-14 aralkyl group such as an ⁇ -naphthyl-C 1-2 alkyl group such as ⁇ -naphthyl methyl; or a pivaloyloxymethyl group.
- a C 1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, or n-butyl
- a C 3-8 cycloalkyl group such as cycl
- the protein molecule of the present invention may have an amidated or esterified carboxyl group (or carboxylate), which is not the carboxyl group at the C-terminus.
- the ester in this case may be, for example, the esters of the C-terminus described above.
- the protein molecule of the present invention further includes molecules having the amino group of the N-terminal amino acid residue protected by a protective group (e.g., a C 1-6 acyl group including a C 1-6 alkanoyl such as a formyl group and an acetyl group), molecules having the N-terminal glutamine residue pyroglutamated that can be formed due to cleavage in vivo; molecules having a substituent (e.g., —OH, —SH, an amino group, an imidazole group, an indole group, and a guanidino group) on a side change of an amino acid in the molecule protected by an appropriate protective group (e.g., a C 1-6 acyl group including a C 1-6 alkanoyl group such as a formyl group and an acetyl group); and the like.
- a protective group e.g., a C 1-6 acyl group including a C 1-6 alkanoyl such as
- the protein molecule of the present invention may be a pharmaceutically acceptable salt formed with an acid or base.
- the salt can be any pharmaceutically acceptable salt, and can be either an acid salt or a basic salt.
- acid salts include inorganic acid salts, such as hydrochloride, hydrobromide, sulfate, nitrate, and phosphate; organic acid salts, such as acetate, propionate, tartarate, fumarate, maleate, malate, citrate, methanesulfonate, and para-toluenesulfonate; and amino acid salts, such as aspartate and glutamate.
- Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; and alkaline-earth metal salts such as calcium salts and magnesium salts.
- the protein molecule of the present invention may be in the form of a solvate.
- the solvent can be any pharmaceutically acceptable solvent, and may be, for example, water, ethanol, glycerol, or acetic acid.
- the protein molecule of the present invention can be easily prepared according to a known genetic engineering method depending on its amino acid sequence.
- the protein molecule can be prepared using PCR, restriction enzyme cleavage, a DNA ligation technique, an in vitro transcription/translation technique, a recombinant protein production technique, etc.
- the protein molecule of the present invention may be purified after synthesis.
- the cells may be recovered from the culture, for example, by centrifugation, filtration, etc., and extracted to give the protein molecule of the present invention.
- the cells may be destroyed by digestion with an enzyme, destruction with osmotic pressure, sudden pressure and decompression, sonication, use of various homogenizers, etc.
- the destroyed cells are then fractionated by physical means such as low-speed centrifugation, ultra-centrifugation, filtration, a molecular sieve, membrane concentration, etc.; or by chemical means such as a precipitating agent, a solubilizing agent, an adsorbent and desorption agent, a dispersing agent, etc.; or by physicochemical means such as electrophoresis, column chromatography, a support, dialysis, salting-out, etc. These techniques may be used in combination. In applying these techniques, physicochemical conditions, such as temperature, pressure, pH, and ion strength, can be suitably set.
- the present invention relates to a polynucleotide comprising the coding sequence of the protein molecule of the present invention, which is a fusion protein (in this specification, sometimes referred to as “polynucleotide of the present invention”).
- polynucleotide of the present invention is described below.
- the coding sequence of the protein molecule of the present invention is not particularly limited as long as the polynucleotide comprises a base sequence encoding the protein molecule of the present invention.
- the polynucleotide of the present invention comprises an expression cassette of the protein molecule of the present invention.
- the expression cassette of the protein molecule of the present invention is not particularly limited as long as it is a DNA that allows expression of the protein molecule of the present invention in cells.
- Typical examples of the expression cassette of the protein molecule of the present invention include a promoter and DNA comprising the coding sequence of the protein molecule of the present invention placed under the control of the promoter.
- Living organisms from which target cells are derived are not particularly limited. Examples include bacteria such as Enterobacteriaceae, fungi such as yeast, animals, and plants. Examples of animals include various mammals such as humans, monkeys, mice, rats, dogs, cats, rabbits, pigs, horses, cows, sheep, goats, and deer; non-mammalian vertebrates and invertebrates; etc. In a preferable embodiment of the present invention, examples of living organisms from which target cells are derived include mammals, E. coli , yeast, Bacillus subtilis , zebrafish, Japanese medaka, and insects. The type of cells is not particularly limited, and cells derived from various tissues or cells having various properties can be used.
- Examples include a blood cell, a hematopoietic stem cell/progenitor cell, a gamete (a sperm, an ovum), a fibroblast cell, an epithelial cell, a vascular endothelial cell, a nerve cell, a liver cell, a keratin-generating cell, a muscle cell, an epidermal cell, an endocrine cell, an ES cell, an iPS cell, a tissue stem cell, and a cancer cell.
- the promoter contained in the expression cassette of the protein molecule of the present invention may be any promoter and can be appropriately selected according to the target cells.
- the promoter for use may be, for example, any pol II promoter.
- pol II promoters include, but are not limited to, a CMV promoter, EF1 promoter, SV40 promoter, MSCV promoter, hTERT promoter, ⁇ -actin promoter, CAG promoter, etc.
- examples of promoters include a tryptophan promoter, such as trc and tac, lac promoter, T7 promoter, T5 promoter, T3 promoter, SP6 promoter, arabinose-induced promoter, cold-shock promoter, and tetracycline-induced promoter.
- the expression cassette of the protein molecule of the present invention may comprise other elements (e.g., multiple cloning sites (MCS), drug resistance genes, replication origins, enhancer sequences, repressor sequences, insulator sequences, reporter protein (e.g., fluorescent protein)-coding sequences, and drug resistance-gene-coding sequences) as necessary.
- MCS multiple cloning sites
- drug resistance genes drug resistance genes
- replication origins enhancer sequences
- repressor sequences e.g., insulator sequences
- reporter protein e.g., fluorescent protein
- drug resistance-gene-coding sequences e.g., drug resistance-coding sequences
- drug resistance genes examples include chloramphenicol resistance genes, tetracycline resistance genes, neomycin resistance genes, erythromycin resistance genes, spectinomycin resistance genes, kanamycin resistance genes, hygromycin resistance genes, puromycin resistance genes, and the like.
- the reporter protein is not particularly limited as long as it is a light-emitting (color-developing) protein capable of reacting with a specific substrate to emit light (develop a color) or a fluorescent protein capable of emitting fluorescence by the action of excited light.
- Examples of the light-emitting (color-developing) protein include luciferase, ⁇ -galactosidase, chloramphenicol acetyltransferase, and ⁇ -glucuronidase.
- fluorescent protein examples include GFP, Azami-Green, ZsGreen, GFP2, HyPer, Sirius, BFP, CFP, Turquoise, Cyan, TFP1, YFP, Venus, ZsYellow, Banana, KusabiraOrange, RFP, DsRed, AsRed, Strawberry, Jred, KillerRed, Cherry, HcRed, and mPlum.
- the expression cassette of the protein molecule of the present invention may constitute a vector by itself or in conjunction with another sequence.
- the type of vector is not particularly limited, and examples include plasmid vectors such as animal cell expression plasmids; virus vectors such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes viruses, and Sendai viruses; and the like.
- examples of vectors include ColE1-based plasmid represented by pBR322 derivative, pACYC plasmid with p15A origin, pSC plasmid, and F factor-derived mini F plasmid such as Bac.
- the polynucleotide of the present invention can be easily prepared according to a known genetic engineering method.
- the polynucleotide can be prepared using PCR, restriction enzyme cleavage, a DNA ligation technique, etc.
- the present invention relates to a composition (in the specification, sometimes referred to as the “composition of the present invention”) comprising at least one member selected from the group consisting of a PcrV antigen and a polynucleotide comprising a PcrV antigen-coding sequence, and at least one member selected from the group consisting of an OprF antigen and a polynucleotide comprising an OprF antigen-coding sequence, an Exotoxin A antigen, and a polynucleotide comprising an Exotoxin A antigen-coding sequence.
- Antigens and polynucleotides are the same as those described in the “2. Protein molecule” section and “Polynucleotide” section.
- the composition of the present invention preferably comprises at least one member selected from the group consisting of a PcrV antigen and a polynucleotide comprising a PcrV antigen-coding sequence, at least one member selected from the group consisting of an OprF antigen and a polynucleotide comprising an OprF antigen-coding sequence, and at least one member selected from the group consisting of an Exotoxin A antigen and a polynucleotide comprising an Exotoxin A antigen-coding sequence.
- polynucleotides When two or more polynucleotides (e.g., the polynucleotide containing the PcrV antigen coding sequence and the polynucleotide containing the OprF antigen coding sequence) are contained, the polynucleotides can be linked to form a single polynucleotide molecule.
- the present invention relates to a drug (in the specification, sometimes referred to as “Drug 1 of the present invention”) comprising at least one member selected from the group consisting of the protein molecule of the present invention, the polynucleotide of the present invention, and the composition of the present invention (in this specification, sometimes referred to as the “active ingredients of the present invention.”) Drug 1 is explained below.
- Drug 1 of the present invention is effective as a vaccine, particularly, an anti- Pseudomonas aeruginosa vaccine.
- Drug 1 of the present invention preferably contains the protein molecule of the present invention in view of the performance as an anti- Pseudomonas aeruginosa vaccine.
- Drug 1 of the present invention can prevent the development of Pseudomonas aeruginosa infection, e.g., sepsis, respiratory tract infection, urinary tract infection, bedsores, liver and biliary system infection, and gastrointestinal tract infection, and reduce the probability of death due to Pseudomonas aeruginosa infection.
- the target organism of Drug 1 of the present invention is not particularly limited as long as it is a living organism that can be infected with Pseudomonas aeruginosa .
- Examples of the organism include various mammals, such as humans, monkeys, mice, rats, dogs, cats, and rabbits. Of these, humans are preferred because Drug 1 of the present invention efficiently exhibits its effects.
- Drug 1 of the present invention is not particularly limited and may contain other components as necessary as long as it contains the active ingredient of the present invention.
- examples of other components include a stabilizer for increasing the heat resistance of the vaccine and an adjuvant as an auxiliary for enhancing antigenicity.
- sugars or amino acids may be used.
- an adjuvant for example, aluminum compounds (e.g., aluminum hydroxide gel), CpG oligodeoxynucleotide, mineral oil, vegetable oil, alum, bentonite, silica, muramyl dipeptide derivatives, thymosin, interleukin, etc. may be used.
- adjuvants include aluminum hydroxide gel, CpG oligodeoxynucleotide (e.g., K3 (K-type CpG ODN) and D35 (D-type CpG ODN), and the like.
- the adjuvants may be used alone or in a combination of two or more.
- examples of Drug 1 of the present invention include bases, carriers, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrates, lubricants, thickeners, humectants, colorants, fragrances, chelating agents, and the like.
- the dosage form of Drug 1 of the present invention is not particularly limited. Examples include an injection, including an aqueous injection, a non-aqueous injection, a suspension injection, and a solid injection; an oral preparation such as a tablet, a capsule, a granule, a powder, a fine granule, a syrup, an enteric preparation, a sustained-release capsule, a chewable tablet, drops, a pill, a liquid or solution for oral application, a lozenge, a sustained-release preparation, and a sustained-release granule; and a preparation for cutaneous application such as a nasal preparation, inhalation, a suppository for rectal application, a pessary, an enema, and a jelly.
- an injection including an aqueous injection, a non-aqueous injection, a suspension injection, and a solid injection
- an oral preparation such as a tablet, a capsule, a granule, a powder, a fine granule,
- the amount of the active ingredient of the present invention in Drug 1 of the present invention depends on the subject of administration, the route of administration, the dosage fault, the condition of the patient, and the determination of the doctor, and is not limited.
- the amount of the active ingredient is, for example, 0.0001 to 95 wt %, and preferably 0.001 to 50 wt %.
- the amount of Drug 1 of the present invention can be determined by a clinical physician, taking into consideration various factors, such as administration route, the health condition of the subject, the subject's age, sex, and body weight, pharmacological findings such as pharmacokinetics and toxicological characteristics, use or non-use of a drug delivery system, and whether Drug 1 is administered as part of a combinational drug with other medicinal agents.
- Drug 1 of the present invention is not particularly limited, but it is preferred that the dosage of the active ingredient of the present invention in a single administration, for example, is 1 ⁇ g to 10 mg/kg (body weight), and 50 to 1000 ⁇ g/kg (body weight).
- the interval and frequency of administration is not particularly limited, and the administration is preferably performed at an interval of about 1 week to 8 weeks for about 1 to 5 times.
- the present invention relates to a drug (in the specification, referred to as “Drug 2 of the present invention”) comprising an antibody against the PcrV antigen and at least one member selected from the group consisting of an antibody against the OprF antigen and an antibody against the Exotoxin A antigen (in the specification, referred to as the “antibody of the present invention.”) Drug 2 is explained below.
- Drug 2 of the present invention is effective as the drug for the treatment of Pseudomonas aeruginosa infection.
- Drug 2 of the present invention preferably contains the antibody against the PcrV antigen, antibody against the OprF antigen, and antibody against the Exotoxin A antigen.
- Drug 2 of the present invention enables the treatment (e.g., reduction, alleviation, or remission of symptoms) of Pseudomonas aeruginosa infection, such as sepsis, respiratory tract infection, urinary tract infection, bedsores, liver and biliary system infection, gastrointestinal tract infection, and the like.
- the type of the antibody examples include a polyclonal antibody, a monoclonal antibody, a human chimeric antibody, a humanized antibody, a fully human antibody, a single-stranded antibody, or an antigen-binding fragment (Fab, F(ab′)2, minibody, scFv-Fc, Fv, scFv, diabody, triabody, and tetrabody.)
- the human chimeric antibody is an antibody in which the variable region of the antibody is a sequence derived from an animal other than a human (e.g. a mouse or cow), and the constant region of the antibody is a sequence derived from a human.
- the antibody of the present invention can also be produced in accordance with these ordinary methods (Current Protocols in Molecular Biology, Chapter 11.12 to 11.13 (2000)).
- the antibody of the present invention is a polyclonal antibody
- the antigen can be immunized in a non-human animal such as a domestic rabbit, and the antibody can be obtained from the serum of the immunized animal according to a usual method.
- a monoclonal antibody as the antibody of the present invention can be obtained from hybridoma cells prepared by immunizing a non-human animal, such as a mouse or a cow, with the antigen (Current Protocols in Molecular Biology, edit. Ausubel et al. (1987), publish. John Wiley and Sons, Section 11.4 to 11.11).
- the antibody can also be produced by increasing immunological reaction by using various adjuvants according to the host.
- adjuvants include, but are not limited to, mineral gels such as Freund's adjuvant and aluminum hydroxide; surface-active substances such as lysolecithin, Pluronic Polyol, polyanion, peptide, oil emulsion, keyhole limpet hemocyanin, and dinitrophenol; and human adjuvants such as BCG (Bacille de Calmette et Guérin) and Corynebacterium parvum.
- the additive, dosage form, and content of an active ingredient (antibody of the present invention) in Drug 2 of the present invention are the same as those in Drug 1 of the present invention.
- the amount of Drug 2 in the present invention can be determined according to the type of usage. If Drug 2 is used for drugs, the amount can be determined by a clinical physician, taking into consideration various factors, such as the administration route, the type of disease, the degree of symptoms, patient's age, sex, and body weight, severity of disease, pharmacological findings such as pharmacokinetics and toxicological characteristics, use or non-use of a drug delivery system, and whether Drug 2 is administered as part of a combinational drug with other medicinal agents.
- Drug 2 of the present invention is not particularly limited. It is preferably used so that the administration amount of the antibody of the present invention per administration is 1 ⁇ g to 10 mg/kg (body weight).
- the interval and frequency of administration is not particularly limited; however, the administration can be performed once to several times (e.g., twice to ten times) per day or per month.
- PcrV, OprF, and Exotoxin A were selected from antigen proteins involving Pseudomonas aeruginosa virulence.
- OprF antigen the partial polypeptide (OprF 198-342 ) of OprF protein was used.
- Exotoxin A antigen a partial polypeptide (mTox 413- ⁇ 578E-638 ) obtained by removing #578 glutamic acid, which was an enzyme active amino acid, by a genetic modification technique from the ToxA 413-538 domain of the C-terminal region containing the enzyme active site of the Exotoxin A protein.
- the total of three gene regions comprising pcrV 1-882 (nucleotide sequence: SEQ ID No. 2) encoding the full-length of PcrV 1-294 (amino acid sequence: SEQ ID No. 1), oprF 594-1028 (nucleotide sequence: SEQ ID No. 4) encoding the intermediate domain region of OprF, OprF 198-342 (amino acid sequence: SEQ ID No.3), and mTox 1239-1916 (nucleotide sequence: SEQ ID No. 6) encoding the C-terminal domain of Exotoxin A, ToxA 413-638 (amino acid sequence: SEQ ID No. 5) was cloned from P.
- linker Oligo DNA encoding glycine serine linkers (-GGGGS- (SEQ ID No.9) and -GSGGSG- (SEQ ID No.10)).
- DNA nucleotide sequence: SEQ ID No.12
- amino acid sequence amino acid sequence: SEQ ID No.
- POmT protein 11
- PcrV 1-294 a GGGGS linker
- OprF 198-342 a GGGGS linker
- GSGGSG a GGGGS linker
- mTox 413- ⁇ 578E-638 mTox 413- ⁇ 578E-638 in this order from the N-terminal side
- TAGzyme registered trademark
- pQE2 QiAGen
- the N-terminal 6 ⁇ His tag amino acid sequence for purification of protein in the vector is “MKHHHHHHHHMHHAKM (SEQ ID No.13),” and the tag portion can be decomposed by DAPase enzyme treatment after purification in an IMAC column.
- the vector was introduced into E. coli , and the resulting E. coli was cultured at 30° C. for 10 hours. The E. coli was then sonicated, and the crushed material was purified in the IMAC column to obtain 6 ⁇ His-tagged POmT ( FIG. 2 ). This was subjected to a DAPase enzyme treatment to decompose the tag portion, thus purifying a gene-recombinant three-antigen protein POmT.
- a PcrV antigen was prepared by the same procedure as in Example 1, except that only the full-length of PcrV 1-294 cloned from Pseudomonas aeruginosa strain PA103 chromosomal DNA was used as an antigen coding sequence.
- OprF antigen was prepared by the same procedure as in Example 1, except that only OprF 198-342 cloned from Pseudomonas aeruginosa strain PA103 chromosomal DNA was used as an antigen coding sequence.
- An mTox antigen was prepared by the same procedure as in Example 1, except that only mTox 413-78E-638 cloned from Pseudomonas aeruginosa strain PA103 chromosomal DNA was used as an antigen coding sequence.
- the vaccine effect of the three-antigen protein POmT was evaluated using a mouse Pseudomonas aeruginosa pneumonia model. Specifically, the evaluation was performed as follows.
- the antibody titer measurement was performed as follows. According to enzyme-linked immunosorbent assay (ELISA), the POmT protein, PcrV 1-294 , OprF 198-342 , and mTox 413- ⁇ 578E-638 were used as antigen proteins, and the titers of antibodies binding to these antigens were quantified by the colorimetric method. The results confirmed that the anti-PcrV titer, anti-OprF titer, and anti-mTox titer were all increased in mice immunized with the three-antigen vaccine protein POmT+Alum ( FIG. 3 ).
- ELISA enzyme-linked immunosorbent assay
- mice were subjected to general anaesthesia with sevoflurane inhalation for a short time period (about 1 minute), and 1 ⁇ 10 6 Pseudomonas aeruginosa PA103 strains were intratracheally administered using a blunt needle.
- the mice were awakened after one minute and allowed to move freely in the cage.
- the number of survivors after 0 hours (before bacterial administration), 4 hours, 8 hours, 12 hours, and 24 hours, and the rectal temperature of the surviving mice was measured and counted as a 24-hour survival rate.
- the lungs of the mice were also removed after 24 hours and quantitatively homogenized to quantify edema.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides a protein molecule effective for an anti-Pseudomonas aeruginosa vaccine. A protein molecule comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.
Description
- The present invention relates to a protein molecule that is effective for an anti-Pseudomonas aeruginosa vaccine, or the like.
- With highly advanced medical care and an ageing population, many fatal infections caused by multidrug-resistant bacteria have been reported. In particular, there has been rapid progress in the development of advanced multidrug resistance in Pseudomonas aeruginosa, which is a highly prevalent organism causing opportunistic infections and ventilator-associated pneumonia (target for intensive care), for which there is a strong need to develop vaccines that strengthen immunity without relying on antimicrobial drugs.
-
Patent Literature 1 discloses immunotherapy using PcrV, a constituent of the type III secretion system.Patent Literature 2 discloses that a fusion protein of OprF and OprI, which is an outer membrane component protein, is effective as an anti-Pseudomonas aeruginosa vaccine. -
- PTL 1: WO2000/33872
- PTL 2: WO2012/084272
- An object of the present invention is to provide a protein molecule effective for an anti-Pseudomonas aeruginosa vaccine.
- In the course of research, the present inventor came to focus on factors that seem to be unrelated to each other, namely PcrV, a component of the type III secretion system, OprF, an outer membrane component protein, and Exotoxin A, an exotoxin secreted by the type II secretion system. In view of the problem described above, the inventor conducted extensive research and found that excellent anti-Pseudomonas aeruginosa vaccine effects can be obtained by combining a PcrV antigen with at least one member selected from the group consisting of an OprF antigen and an Exotoxin A antigen. The inventor conducted further extensive research based on the above finding, and accomplished the present invention. Specifically, the present invention includes the following aspects.
-
Item 1. A protein molecule comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.
Item 2. The protein molecule according toItem 1, wherein the domains are linked individually via a linker.
Item 3. The protein molecule according toItem
Item 4. The protein molecule according toItem 3, wherein the PcrV antigen domain, OprF antigen domain, and Exotoxin A antigen domain are arranged in this order.
Item 5. The protein molecule according to any one ofItems 1 to 4, which is a fusion protein.
Item 6. The protein molecule according to Item 5, wherein the number of amino acid residues is 700 or less.
Item 7. A polynucleotide comprising a coding sequence of the protein molecule according to Item 5 or 6.
Item 8. A composition comprising at least one member selected from the group consisting of a PcrV antigen and a polynucleotide comprising a PcrV antigen-coding sequence, and at least one member selected from the group consisting of an OprF antigen, a polynucleotide comprising an OprF antigen-coding sequence, an Exotoxin A antigen, and a polynucleotide comprising an Exotoxin A antigen-coding sequence.
Item 9. A drug comprising at least one member selected from the group consisting of the protein molecule according to any one ofItems 1 to 6, the polynucleotide according to Item 7, and the composition according toItem 8.
Item 10. The drug according to Item 9, which is an anti-Pseudomonas aeruginosa vaccine.
Item 11. A drug comprising an antibody against a PcrV antigen, and at least one member selected from the group consisting of an antibody against an OprF antigen and an antibody against an Exotoxin A antigen.
Item 12. The drug according toItem 11, which is for use in the treatment of Pseudomonas aeruginosa infection. - The present invention provides a protein molecule, a polynucleotide, and a composition, each being effective for an anti-Pseudomonas aeruginosa vaccine, a combination of antibodies effective for the treatment of Pseudomonas aeruginosa infection, etc.
-
FIG. 1 shows a vector map of a vector for generation of a gene-recombinant three-antigen protein POmT. -
FIG. 2 shows a CBB-stained image of SDS-PAGE gel of a sample in each stage in the purification of the gene-recombinant three-antigen protein POmT. -
FIG. 3 shows the results of antibody titer measurement (Test Example 1). The horizontal axis shows samples administered as vaccines. The bars indicate antigen samples used for ELISA assay. -
FIG. 4 shows the mouse survival rate after pulmonary administration of Pseudomonas aeruginosa. The horizontal axis shows the time elapsed from the administration of Pseudomonas aeruginosa. The lines indicate samples administered as vaccines. -
FIG. 5 shows the quantification results of pulmonary edema in mice after pulmonary administration of Pseudomonas aeruginosa. The vertical axis shows pulmonary edema (the ratio of wet weight to dry weight) and the horizontal axis shows tested groups (demonstrating the sample name administered as a vaccine). - In the present specification, the terms “comprising,” “containing,” and “including” include the concepts of comprising, containing, consisting essentially of, and consisting of.
- In the present specification, the “identity” of amino acid sequences refers to the degree to which two or more contrastable amino acid sequences match each other. Thus, the higher the degree of match between two amino acid sequences, the higher the identity or similarity of those sequences. The level of amino acid sequence identity is determined, for example, by using FASTA (a tool for sequence analysis) with default parameters. Alternatively, the level of amino acid sequence identity can be determined by using the BLAST algorithm by Karlin and Altschul (Karlin S, Altschul SF. Methods for assessing the statistical significance of molecular sequence features by using general scorings schemes, Proc Natl Acad Sci USA. 87: 2264-2268(1990), Karlin S, Altschul SF. Applications and statistics for multiple high-scoring segments in molecular sequences, Proc Natl Acad Sci USA. 90: 5873-7(1993)). A program called “BLASTX,” based on this BLAST algorithm, has been developed. The specific techniques of these analysis methods are known and can be found on the website of the National Center of Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/). The “identity” of base sequences is also defined in the same manner as above.
- In the present specification, “conservative substitution” means the substitution of an amino acid residue with an amino acid residue having a similar side chain. For example, the substitution between amino acid residues having a basic side chain such as lysine, arginine, or histidine is considered to be a conservative substitution. The following substitutions between other amino acid residues are also considered to be a conservative substitution: the substitution between amino acid residues having an acidic side chain such as aspartic acid or glutamic acid; the substitution between amino acid residues having an uncharged polar side chain such as glycine, asparagine, glutamine, serine, threonine, tyrosine, or cysteine; the substitution between amino acid residues having a nonpolar side chain such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or tryptophan; the substitution between amino acid residues having a β-branched side chain such as threonine, valine, or isoleucine; and the substitution between amino acid residues having an aromatic side chain such as tyrosine, phenylalanine, tryptophan, or histidine.
- In the present specification, polynucleotides, such as DNA or RNA, may be chemically modified DNA or RNA as described below. To prevent the degradation by hydrolases such as nucleases, the phosphate residue (phosphate) of each nucleotide can be substituted with, for example, a chemically modified phosphate residue such as phosphorothioate (PS), methylphosphonate, or phosphorodithionate. The hydroxyl group at
position 2 of the ribose of each ribonucleotide may also be substituted with —OR (R represents, for example, CH3(2′-O-Me), CH2CH2OCH3(2′-O-MOE), CH2CH2NHC(NH)NH2, CH2CONHCH3, or CH2CH2CN). Additionally, the base moiety (pyrimidine, purine) may be chemically modified, by, for example, introduction of a methyl group or a cationic functional group into positon 5 of the pyrimidine base, or substitution of the carbonyl group atposition 2 with thiocarbonyl. Additionally, the polynucleotide of the present invention also includes, but is not limited to, those formed by modifying the phosphate moiety or the hydroxyl portion, for example, by biotin, an amino group, a lower alkyl amine group, or an acetyl group. A BNA (LNA) and the like, in which the conformation of the sugar moiety is immobilized in the N form by bridging the 2′oxygen and 4′carbon in the sugar moiety of the nucleotide, can also be used. - In the present specification, the “coding sequence” is not particularly limited as long as it is a nucleotide sequence encoding an amino acid sequence of a protein.
- In one embodiment, the present invention relates to a protein molecule (in this specification, sometimes referred to as “protein molecule of the invention”) comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains. This is explained below.
- The PcrV antigen is not particularly limited as long as it is a peptide comprising a full or partial amino acid sequence of PcrV protein. The PcrV antigen domain is a partial domain comprising the protein molecule of the present invention, and is a domain comprising a PcrV antigen.
- The PcrV protein is a protein constituting the type III secretion system of Pseudomonas aeruginosa, and is one of the proteins that constitute the needle tip region of the type III secretion apparatus.
- The Pseudomonas aeruginosa strain derived from the PcrV protein is not particularly limited. Examples of the Pseudomonas aeruginosa strain include PA103, PAO1, PA14, PACS2, PAK, C3719, VRFPA04, and the like.
- The amino acid sequences of various PcrV proteins are known, or can be predicted from known amino acid sequences and based on genomic information of a strain (e.g., a known strain or a newly obtained strain), or can be identified by cloning based on known amino acid sequences. For example, the amino acid sequence of the PcrV protein in Pseudomonas aeruginosa strain PA103 is the amino acid sequence represented by SEQ ID No. 1, and the amino acid sequence of the PcrV protein in Pseudomonas aeruginosa strain PAO1 is the amino acid sequence represented by SEQ ID No. 14.
- The partial amino acid sequence of the PcrV protein is not particularly limited as long as it is a contiguous amino acid sequence of sufficient length to be used as a PcrV antigen, i.e., to induce an antibody in the PcrV protein amino acid sequence. The number of constituent amino acid residues of the partial amino acid sequence is, for example, 12 or more. In view of the performance of the protein molecule of the present invention as an anti-Pseudomonas aeruginosa vaccine, the number of amino acid residues is preferably 20 or more, more preferably 50 or more, even more preferably 100 or more, still more preferably 150 or more, and further preferably 200 or more.
- The partial amino acid sequence of the PcrV protein preferably includes the C-terminal region, e.g., the amino acid region 144th to 257th from the N-terminus of SEQ ID No. 1 or No. 14, in view of the performance of the protein molecule of the present invention, as an anti-Pseudomonas aeruginosa vaccine.
- The full or partial amino acid sequence of the PcrV protein may have an amino acid substitution, deletion, addition, insertion, and like mutation against the full or partial amino acid sequence of the wild-type PcrV protein. The mutation is preferably a substitution, and more preferably a conservative substitution. If the full or partial amino acid sequence of the PcrV protein has an amino acid mutation, it has, for example, at least 90%, preferably at least 95%, more preferably at least 98%, and even more preferably at least 99% identity with the full or partial amino acid sequence of the wild PcrV protein.
- Preferable examples of the full or partial amino acid sequence of PcrV protein include the amino acid sequences described in (a) and (b) below:
- At least one member selected from the group consisting of
- (a) the full or partial amino acid sequence of a wild PcrV protein (e.g., the amino acid sequence represented by SEQ ID No. 1 or No. 14, or a partial amino acid sequence thereof), and (b) the amino acid sequence having at least 90% identity with the full or partial amino acid sequence of a wild PcrV protein (e.g., the amino acid sequence represented by SEQ ID No. 1 or No. 14, or a partial amino acid sequence thereof).
- In (b) above, the identity is preferably at least 95%, more preferably at least 98%, and even more preferably at least 99%. The number of amino acids mutated in (b) above is preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and still more preferably 1 to 2.
- The number of PcrV antigen domains contained in the protein molecule of the present invention is typically one, but can be two or more (e.g., 2 to 6, 2 to 4, or 2 to 3). However, from the viewpoint of suppressing the molecular weight of the protein molecule of the present invention and facilitating the preparation, administration, and metabolism after administration, the number of PcrV antigen domains is preferably small, and particularly preferably one.
- The OprF antigen is not particularly limited as long as it is a peptide comprising the full or partial amino acid sequence of the OprF protein. The OprF antigen domain is a partial domain constituting the protein molecule of the present invention, and is a domain comprising an OprF antigen.
- The OprF protein is a protein composing porin of the outer membrane of Pseudomonas aeruginosa.
- The Pseudomonas aeruginosa strain from which the OprF protein is derived is the same as the Pseudomonas aeruginosa strain from which the PcrV protein is derived.
- The amino acid sequences of various OprF proteins are known or can be predicted from known amino acid sequences and based on genomic information of a strain (e.g., a known strain or a newly obtained strain), or can be identified by cloning based on known amino acid sequences. For example, the amino acid sequence of the OprF protein in Pseudomonas aeruginosa strains PA103 and PA01 is the amino acid sequence represented by SEQ ID No. 15, and a mature amino acid sequence thereof (e.g., an amino acid sequence from which a signal peptide sequence is removed).
- The partial amino acid sequence of the OprF protein is not particularly limited as long as it is a contiguous amino acid sequence of sufficient length to be used as an OprF antigen, i.e., to induce an antibody in the OprF protein amino acid sequence. The number of constituent amino acid residues of the partial amino acid sequence is, for example, 12 or more. In terms of the performance of the protein molecule of the present invention as an anti-Pseudomonas aeruginosa vaccine, the number of amino acid residues is preferably 20 or more, more preferably 50 or more, even more preferably 100 or more, and still more preferably 120 or more.
- In terms of suppressing the molecular weight of the protein molecule of the present invention, and facilitating the preparation, administration, and metabolism after administration, the partial amino acid sequence of the OprF protein is preferably used as an OprF antigen, in which case, the number of amino acid residues is preferably 250 or less, more preferably 200 or less, even more preferably 170 or less, and still more preferably 160 or less.
- The partial amino acid sequence of the OprF protein preferably includes a region containing an intermediate domain, e.g., the amino acid region 198th to 342nd (e.g., SEQ ID No. 3) from the N-terminus of SEQ ID No. 15, in view of the performance of the protein molecule of the present invention as an anti-Pseudomonas aeruginosa vaccine.
- The full or partial amino acid sequence of the OprF protein may have an amino acid substitution, deletion, addition, insertion, and like mutation against the full or partial amino acid sequence of the wild-type OprF protein. The mutation is preferably a substitution, and more preferably a conservative substitution. If the full or partial amino acid sequence of the OprF protein has an amino acid mutation, it has, for example, at least 90%, preferably at least 95%, more preferably at least 98%, and even more preferably at least 99% identity with the full or partial amino acid sequence of the wild OprF protein.
- Preferable examples of the full or partial amino acid sequence of OprF protein include the amino acid sequences described in (c) and (d) below:
- At least one member selected from the group consisting of
- (c) the full or partial amino acid sequence of a wild OprF protein (e.g., the amino acid sequence represented by SEQ ID No. 15, or a partial amino acid sequence thereof, or the amino acid sequence comprising the amino acid sequence represented by SEQ ID No. 3), and
(d) the amino acid sequence having at least 90% identity with the full or partial amino acid sequence of a wild OprF protein (e.g., the amino acid sequence represented by SEQ ID No. 15, or a partial amino acid sequence thereof, or the amino acid sequence comprising the amino acid sequence represented by SEQ ID No. 3). - In (d) above, the identity is preferably at least 95%, more preferably at least 98%, and even more preferably at least 99%. The number of amino acids mutated in (d) above is preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and still more preferably 1 to 2.
- The number of OprF antigen domains contained in the protein molecule of the present invention is typically one, but can be two or more (e.g., 2 to 6, 2 to 4, or 2 to 3). However, from the viewpoint of suppressing the molecular weight of the protein molecule of the present invention and facilitating the preparation, administration, and metabolism after administration, the number of OprF antigen domains is preferably small, and particularly preferably one.
- The Exotoxin A antigen is not particularly limited as long as it is a peptide comprising the full or partial amino acid sequence of Exotoxin A protein. The Exotoxin A antigen domain is a partial domain constituting the protein molecule of the present invention, and a domain comprising the Exotoxin A antigen.
- The Exotoxin A protein is the main cytotoxic in which Pseudomonas aeruginosa is secreted in a type II secretion mode.
- The Pseudomonas aeruginosa strain from which the Exotoxin A protein is derived is the same as the Pseudomonas aeruginosa strain from which the PcrV protein is derived.
- The amino acid sequences of various Exotoxin A proteins are known or can be predicted from known amino acid sequences and can be predicted based on genomic information of a strain (e.g., a known strain or a newly obtained strain), or can be identified by cloning based on known amino acid sequences. For example, the amino acid sequence of the Exotoxin A protein in Pseudomonas aeruginosa strain PA103 is the amino acid sequence represented by SEQ ID No. 16, and mature amino acid sequence thereof (e.g., an amino acid sequence from which a signal peptide sequence is removed).
- The partial amino acid sequence of the Exotoxin A protein is not particularly limited as long as it is a contiguous amino acid sequence of sufficient length to be used as an Exotoxin A, i.e., to induce an antibody in the Exotoxin A protein amino acid sequence. The number of constituent amino acid residues of the partial amino acid sequence is, for example, 12 or more. In terms of the performance of the protein molecule of the present invention as an anti-Pseudomonas aeruginosa vaccine, the number of amino acid residues is preferably 20 or more, more preferably 50 or more, even more preferably 100 or more, still more preferably 150 or more, and further more preferably 200 or more.
- From the viewpoint of suppressing the molecular weight of the protein molecule of the present invention and facilitating the preparation, administration, and metabolism after administration, the partial amino acid sequence of the Exotoxin A protein is preferably used as an Exotoxin A antigen. In this case, the number of amino acid residues is preferably 500 or less, more preferably 400 or less, even more preferably 300 or less, and further preferably 250 or less.
- The partial amino acid sequence of the Exotoxin A protein preferably includes a region containing an enzyme active site, e.g., the amino acid region 413rd to 638th from the N-terminus of SEQ ID No. 16 (e.g., SEQ ID No. 5), in view of the performance of the protein molecule of the present invention, as an anti-Pseudomonas aeruginosa vaccine.
- The full or partial amino acid sequence of the Exotoxin A protein may have an amino acid substitution, deletion, addition, insertion, and like mutation against the full or partial amino acid sequence of the wild-type Exotoxin A protein. The mutation is preferably a substitution, and more preferably a conservative substitution. If the full or partial amino acid sequence of the Exotoxin A protein has an amino acid mutation, it has, for example, at least 90%, preferably at least 95%, more preferably at least 98%, and even more preferably at least 99% identity with the full or partial amino acid sequence of the wild Exotoxin A protein.
- In the full or partial amino acid sequence of the Exotoxin A protein, the enzyme-active amino acid of Exotoxin A (in the case of SEQ ID No. 16, the 578th amino acid (glutamic acid) from the N-terminus) is preferably deleted. This can reduce side effects in the administration subject.
- Preferable examples of the full or partial amino acid sequence of Exotoxin A protein include the amino acid sequences described in (e) and (f) below:
- At least one member selected from the group consisting of
- (e) the full or partial amino acid sequence of wild Exotoxin A protein (e.g., the amino acid sequence represented by SEQ ID No. 16, or a partial amino acid sequence thereof, or the amino acid sequence comprising the amino acid sequence represented by SEQ ID No. 5), and
(f) the amino acid sequence having at least 90% identity with the full or partial amino acid sequence of wild Exotoxin A protein (e.g., the amino acid sequence represented by SEQ ID No. 16, or a partial amino acid sequence thereof, or the amino acid sequence comprising the amino acid sequence represented by SEQ ID No. 5). - In (f) above, the identity is preferably at least 95%, more preferably at least 98%, and even more preferably at least 99%. The number of mutated amino acids in (d) above is preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and still more preferably 1 to 2.
- The number of Exotoxin A antigen domains contained in the protein molecule of the present invention is typically one, but can be two or more (e.g., 2 to 6, 2 to 4, and 2 to 3). However, from the viewpoint of suppressing the molecular weight of the protein molecule of the present invention, and facilitating preparation, administration, and metabolism after administration, the number of Exotoxin A antigen domains is preferably small, and particularly preferably one.
- In the protein molecule of the present invention, the domains (e.g., between the PcrV antigen domain and the OprF antigen domain, between the PcrV antigen domain and the Exotoxin A antigen domain, between the OprF antigen domain and the Exotoxin A antigen domain, etc.,) are each directly or indirectly linked.
- When the domains are directly linked, the linkage may be due to peptide bonding or other chemical cross-linking (e.g., carbodiimide chemistry, reductive animation, cyanylation chemistry (e.g., CDAP chemistry), maleimide chemistry, hydrazide chemistry, ester chemistry, and N-hydroxy succinic acid imide chemistry.)
- When the domains are indirectly linked, they are preferably linked via a linker. Examples of the linker include peptide linkers, chemically cross-linked linkers (e.g., linkers having 4 to 12 carbon atoms, bifunctional linkers, linkers containing one or two reactive amino groups at the end, B-proprionamido, nitrophenylethylamine, haloacyl halide, 6-aminocaproic acid, and ADH). Preferable examples include peptide linkers.
- In the protein molecule of the present invention, the domains are each preferably linked via a linker. In particular, it is particularly preferable in the protein molecule of the present invention that the domains are each linked via a peptide linker (i.e., the protein molecule of the present invention is a fusion protein). This allows the protein molecule of the present invention to be stably isolated and purified using genetic recombination technology, enabling achievement of high performance as an anti-Pseudomonas aeruginosa vaccine.
- The peptide linker is not particularly limited as long as it functions as a linker. It is preferable that the peptide linker is an amino acid sequence that does not foam a secondary structure, such as α-helix structure or β-sheet structure, and that it is freely foldable. The peptide linker is preferably an amino acid sequence consisting of units of several amino acid residues linked. The peptide linker is preferably a linker (GS linker) comprising glycine and serine. Specific examples include GGGGS (SEQ ID No. 17), GSG, SAGG (SEQ ID No. 18), GGGS (SEQ ID No. 19), or GGSG (SEQ ID No. 20) as a constituent unit. The number of amino acid residues in the peptide linker is not particularly limited, and is, for example, 3 or more, preferably 3 to 20, and more preferably 4 to 10. By keeping the number of amino acid residues in the peptide linker at this level, the molecular weight of the protein molecule of the present invention can be reduced, and the preparation, administration, and metabolism after administration can be facilitated.
- In view of the performance of the protein molecule of the present invention as an anti-Pseudomonas aeruginosa vaccine, it is particularly preferred to contain three domains (PcrV antigen domain, OprF antigen domain, and Exotoxin A antigen domain). In this case, from the same viewpoint, the PcrV antigen domain, the OprF antigen domain, and the Exotoxin A antigen domain are preferably arranged in this order. If the protein molecule of the present invention is a fusion protein, the PcrV antigen domain, the OprF antigen domain, and the Exotoxin A antigen domain are preferably arranged in this order from the N-terminus.
- The protein molecule of the present invention may contain amino acid sequences other than those listed above (e.g., tag sequence and other antigen domain sequences).
- The number of amino acid residues constituting the protein molecule of the present invention is preferably 1000 or less, more preferably 900 or less, even more preferably 800 or less, and particularly preferably 700 or less, from the viewpoint of facilitating preparation, administration, and metabolism after administration. In view of the performance as the anti-Pseudomonas aeruginosa vaccine, the number of amino acid residues is preferably 400 or more, more preferably 500 or more, and even more preferably 600 or more.
- The protein molecule of the present invention may be chemically modified as long as the function as an anti-Pseudomonas aeruginosa vaccine is not greatly impaired.
- The protein molecule of the present invention may have a carboxyl group (—COOH), carboxylate (—COO−), amide (—CONH2), or ester (—COOR) at the C-terminus.
- “R” in the ester is, for example, a C1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, or n-butyl; a C3-8 cycloalkyl group such as cyclopentyl or cyclohexyl; a C6-12 aryl group such as phenyl or α-naphthyl; a phenyl-C1-2 alkyl group such as benzyl or phenethyl; a C7-14 aralkyl group such as an α-naphthyl-C1-2 alkyl group such as α-naphthyl methyl; or a pivaloyloxymethyl group.
- The protein molecule of the present invention may have an amidated or esterified carboxyl group (or carboxylate), which is not the carboxyl group at the C-terminus. The ester in this case may be, for example, the esters of the C-terminus described above.
- The protein molecule of the present invention further includes molecules having the amino group of the N-terminal amino acid residue protected by a protective group (e.g., a C1-6 acyl group including a C1-6 alkanoyl such as a formyl group and an acetyl group), molecules having the N-terminal glutamine residue pyroglutamated that can be formed due to cleavage in vivo; molecules having a substituent (e.g., —OH, —SH, an amino group, an imidazole group, an indole group, and a guanidino group) on a side change of an amino acid in the molecule protected by an appropriate protective group (e.g., a C1-6 acyl group including a C1-6 alkanoyl group such as a formyl group and an acetyl group); and the like.
- The protein molecule of the present invention may be a pharmaceutically acceptable salt formed with an acid or base. The salt can be any pharmaceutically acceptable salt, and can be either an acid salt or a basic salt. Examples of acid salts include inorganic acid salts, such as hydrochloride, hydrobromide, sulfate, nitrate, and phosphate; organic acid salts, such as acetate, propionate, tartarate, fumarate, maleate, malate, citrate, methanesulfonate, and para-toluenesulfonate; and amino acid salts, such as aspartate and glutamate. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; and alkaline-earth metal salts such as calcium salts and magnesium salts.
- The protein molecule of the present invention may be in the form of a solvate. The solvent can be any pharmaceutically acceptable solvent, and may be, for example, water, ethanol, glycerol, or acetic acid.
- The protein molecule of the present invention can be easily prepared according to a known genetic engineering method depending on its amino acid sequence. For example, the protein molecule can be prepared using PCR, restriction enzyme cleavage, a DNA ligation technique, an in vitro transcription/translation technique, a recombinant protein production technique, etc.
- The protein molecule of the present invention may be purified after synthesis. The cells may be recovered from the culture, for example, by centrifugation, filtration, etc., and extracted to give the protein molecule of the present invention. At the first step of extraction, the cells may be destroyed by digestion with an enzyme, destruction with osmotic pressure, sudden pressure and decompression, sonication, use of various homogenizers, etc. The destroyed cells are then fractionated by physical means such as low-speed centrifugation, ultra-centrifugation, filtration, a molecular sieve, membrane concentration, etc.; or by chemical means such as a precipitating agent, a solubilizing agent, an adsorbent and desorption agent, a dispersing agent, etc.; or by physicochemical means such as electrophoresis, column chromatography, a support, dialysis, salting-out, etc. These techniques may be used in combination. In applying these techniques, physicochemical conditions, such as temperature, pressure, pH, and ion strength, can be suitably set.
- In one embodiment, the present invention relates to a polynucleotide comprising the coding sequence of the protein molecule of the present invention, which is a fusion protein (in this specification, sometimes referred to as “polynucleotide of the present invention”). The polynucleotide is described below.
- The coding sequence of the protein molecule of the present invention is not particularly limited as long as the polynucleotide comprises a base sequence encoding the protein molecule of the present invention.
- In one embodiment, the polynucleotide of the present invention comprises an expression cassette of the protein molecule of the present invention.
- The expression cassette of the protein molecule of the present invention is not particularly limited as long as it is a DNA that allows expression of the protein molecule of the present invention in cells. Typical examples of the expression cassette of the protein molecule of the present invention include a promoter and DNA comprising the coding sequence of the protein molecule of the present invention placed under the control of the promoter.
- Living organisms from which target cells are derived are not particularly limited. Examples include bacteria such as Enterobacteriaceae, fungi such as yeast, animals, and plants. Examples of animals include various mammals such as humans, monkeys, mice, rats, dogs, cats, rabbits, pigs, horses, cows, sheep, goats, and deer; non-mammalian vertebrates and invertebrates; etc. In a preferable embodiment of the present invention, examples of living organisms from which target cells are derived include mammals, E. coli, yeast, Bacillus subtilis, zebrafish, Japanese medaka, and insects. The type of cells is not particularly limited, and cells derived from various tissues or cells having various properties can be used. Examples include a blood cell, a hematopoietic stem cell/progenitor cell, a gamete (a sperm, an ovum), a fibroblast cell, an epithelial cell, a vascular endothelial cell, a nerve cell, a liver cell, a keratin-generating cell, a muscle cell, an epidermal cell, an endocrine cell, an ES cell, an iPS cell, a tissue stem cell, and a cancer cell.
- The promoter contained in the expression cassette of the protein molecule of the present invention may be any promoter and can be appropriately selected according to the target cells. The promoter for use may be, for example, any pol II promoter. Examples of pol II promoters include, but are not limited to, a CMV promoter, EF1 promoter, SV40 promoter, MSCV promoter, hTERT promoter, β-actin promoter, CAG promoter, etc. In addition, examples of promoters include a tryptophan promoter, such as trc and tac, lac promoter, T7 promoter, T5 promoter, T3 promoter, SP6 promoter, arabinose-induced promoter, cold-shock promoter, and tetracycline-induced promoter.
- The expression cassette of the protein molecule of the present invention may comprise other elements (e.g., multiple cloning sites (MCS), drug resistance genes, replication origins, enhancer sequences, repressor sequences, insulator sequences, reporter protein (e.g., fluorescent protein)-coding sequences, and drug resistance-gene-coding sequences) as necessary. MCS is not particularly limited as long as it contains multiple (e.g., 2 to 50, preferably 2 to 20, and more preferably 2 to 10) restriction enzyme sites. If the protein molecule of the present invention does not contain a functional domain, the MCS can be used for insertion of the coding sequence of any functional domain.
- Examples of drug resistance genes include chloramphenicol resistance genes, tetracycline resistance genes, neomycin resistance genes, erythromycin resistance genes, spectinomycin resistance genes, kanamycin resistance genes, hygromycin resistance genes, puromycin resistance genes, and the like.
- The reporter protein is not particularly limited as long as it is a light-emitting (color-developing) protein capable of reacting with a specific substrate to emit light (develop a color) or a fluorescent protein capable of emitting fluorescence by the action of excited light. Examples of the light-emitting (color-developing) protein include luciferase, β-galactosidase, chloramphenicol acetyltransferase, and β-glucuronidase. Examples of the fluorescent protein include GFP, Azami-Green, ZsGreen, GFP2, HyPer, Sirius, BFP, CFP, Turquoise, Cyan, TFP1, YFP, Venus, ZsYellow, Banana, KusabiraOrange, RFP, DsRed, AsRed, Strawberry, Jred, KillerRed, Cherry, HcRed, and mPlum.
- The expression cassette of the protein molecule of the present invention may constitute a vector by itself or in conjunction with another sequence. The type of vector is not particularly limited, and examples include plasmid vectors such as animal cell expression plasmids; virus vectors such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes viruses, and Sendai viruses; and the like. In addition to the above, examples of vectors include ColE1-based plasmid represented by pBR322 derivative, pACYC plasmid with p15A origin, pSC plasmid, and F factor-derived mini F plasmid such as Bac.
- The polynucleotide of the present invention can be easily prepared according to a known genetic engineering method. For example, the polynucleotide can be prepared using PCR, restriction enzyme cleavage, a DNA ligation technique, etc.
- In one embodiment, the present invention relates to a composition (in the specification, sometimes referred to as the “composition of the present invention”) comprising at least one member selected from the group consisting of a PcrV antigen and a polynucleotide comprising a PcrV antigen-coding sequence, and at least one member selected from the group consisting of an OprF antigen and a polynucleotide comprising an OprF antigen-coding sequence, an Exotoxin A antigen, and a polynucleotide comprising an Exotoxin A antigen-coding sequence.
- Antigens and polynucleotides are the same as those described in the “2. Protein molecule” section and “Polynucleotide” section.
- In view of the performance as the anti-Pseudomonas aeruginosa vaccine, the composition of the present invention preferably comprises at least one member selected from the group consisting of a PcrV antigen and a polynucleotide comprising a PcrV antigen-coding sequence, at least one member selected from the group consisting of an OprF antigen and a polynucleotide comprising an OprF antigen-coding sequence, and at least one member selected from the group consisting of an Exotoxin A antigen and a polynucleotide comprising an Exotoxin A antigen-coding sequence.
- When two or more polynucleotides (e.g., the polynucleotide containing the PcrV antigen coding sequence and the polynucleotide containing the OprF antigen coding sequence) are contained, the polynucleotides can be linked to form a single polynucleotide molecule.
- In one embodiment, the present invention relates to a drug (in the specification, sometimes referred to as “
Drug 1 of the present invention”) comprising at least one member selected from the group consisting of the protein molecule of the present invention, the polynucleotide of the present invention, and the composition of the present invention (in this specification, sometimes referred to as the “active ingredients of the present invention.”)Drug 1 is explained below. -
Drug 1 of the present invention is effective as a vaccine, particularly, an anti-Pseudomonas aeruginosa vaccine.Drug 1 of the present invention preferably contains the protein molecule of the present invention in view of the performance as an anti-Pseudomonas aeruginosa vaccine.Drug 1 of the present invention can prevent the development of Pseudomonas aeruginosa infection, e.g., sepsis, respiratory tract infection, urinary tract infection, bedsores, liver and biliary system infection, and gastrointestinal tract infection, and reduce the probability of death due to Pseudomonas aeruginosa infection. - The target organism of
Drug 1 of the present invention is not particularly limited as long as it is a living organism that can be infected with Pseudomonas aeruginosa. Examples of the organism include various mammals, such as humans, monkeys, mice, rats, dogs, cats, and rabbits. Of these, humans are preferred becauseDrug 1 of the present invention efficiently exhibits its effects. -
Drug 1 of the present invention is not particularly limited and may contain other components as necessary as long as it contains the active ingredient of the present invention. Examples of other components include a stabilizer for increasing the heat resistance of the vaccine and an adjuvant as an auxiliary for enhancing antigenicity. - As a stabilizer, for example, sugars or amino acids may be used. As an adjuvant, for example, aluminum compounds (e.g., aluminum hydroxide gel), CpG oligodeoxynucleotide, mineral oil, vegetable oil, alum, bentonite, silica, muramyl dipeptide derivatives, thymosin, interleukin, etc. may be used. Preferable examples of adjuvants include aluminum hydroxide gel, CpG oligodeoxynucleotide (e.g., K3 (K-type CpG ODN) and D35 (D-type CpG ODN), and the like. The adjuvants may be used alone or in a combination of two or more.
- In addition to the above, examples of
Drug 1 of the present invention include bases, carriers, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrates, lubricants, thickeners, humectants, colorants, fragrances, chelating agents, and the like. - The dosage form of
Drug 1 of the present invention is not particularly limited. Examples include an injection, including an aqueous injection, a non-aqueous injection, a suspension injection, and a solid injection; an oral preparation such as a tablet, a capsule, a granule, a powder, a fine granule, a syrup, an enteric preparation, a sustained-release capsule, a chewable tablet, drops, a pill, a liquid or solution for oral application, a lozenge, a sustained-release preparation, and a sustained-release granule; and a preparation for cutaneous application such as a nasal preparation, inhalation, a suppository for rectal application, a pessary, an enema, and a jelly. - The amount of the active ingredient of the present invention in
Drug 1 of the present invention depends on the subject of administration, the route of administration, the dosage fault, the condition of the patient, and the determination of the doctor, and is not limited. For example, the amount of the active ingredient is, for example, 0.0001 to 95 wt %, and preferably 0.001 to 50 wt %. - The amount of
Drug 1 of the present invention can be determined by a clinical physician, taking into consideration various factors, such as administration route, the health condition of the subject, the subject's age, sex, and body weight, pharmacological findings such as pharmacokinetics and toxicological characteristics, use or non-use of a drug delivery system, and whetherDrug 1 is administered as part of a combinational drug with other medicinal agents.Drug 1 of the present invention is not particularly limited, but it is preferred that the dosage of the active ingredient of the present invention in a single administration, for example, is 1 μg to 10 mg/kg (body weight), and 50 to 1000 μg/kg (body weight). The interval and frequency of administration is not particularly limited, and the administration is preferably performed at an interval of about 1 week to 8 weeks for about 1 to 5 times. - In one embodiment, the present invention relates to a drug (in the specification, referred to as “
Drug 2 of the present invention”) comprising an antibody against the PcrV antigen and at least one member selected from the group consisting of an antibody against the OprF antigen and an antibody against the Exotoxin A antigen (in the specification, referred to as the “antibody of the present invention.”)Drug 2 is explained below. - The antigens are the same as in the explanation in the “2. Protein molecule” section.
Drug 2 of the present invention is effective as the drug for the treatment of Pseudomonas aeruginosa infection. From the viewpoint of treatment effects,Drug 2 of the present invention preferably contains the antibody against the PcrV antigen, antibody against the OprF antigen, and antibody against the Exotoxin A antigen.Drug 2 of the present invention enables the treatment (e.g., reduction, alleviation, or remission of symptoms) of Pseudomonas aeruginosa infection, such as sepsis, respiratory tract infection, urinary tract infection, bedsores, liver and biliary system infection, gastrointestinal tract infection, and the like. - Examples of the type of the antibody include a polyclonal antibody, a monoclonal antibody, a human chimeric antibody, a humanized antibody, a fully human antibody, a single-stranded antibody, or an antigen-binding fragment (Fab, F(ab′)2, minibody, scFv-Fc, Fv, scFv, diabody, triabody, and tetrabody.) The human chimeric antibody is an antibody in which the variable region of the antibody is a sequence derived from an animal other than a human (e.g. a mouse or cow), and the constant region of the antibody is a sequence derived from a human.
- Methods for producing these antibodies are already well known, and the antibody of the present invention can also be produced in accordance with these ordinary methods (Current Protocols in Molecular Biology, Chapter 11.12 to 11.13 (2000)). Specifically, when the antibody of the present invention is a polyclonal antibody, the antigen can be immunized in a non-human animal such as a domestic rabbit, and the antibody can be obtained from the serum of the immunized animal according to a usual method. A monoclonal antibody as the antibody of the present invention can be obtained from hybridoma cells prepared by immunizing a non-human animal, such as a mouse or a cow, with the antigen (Current Protocols in Molecular Biology, edit. Ausubel et al. (1987), publish. John Wiley and Sons, Section 11.4 to 11.11).
- The antibody can also be produced by increasing immunological reaction by using various adjuvants according to the host. Examples of such adjuvants include, but are not limited to, mineral gels such as Freund's adjuvant and aluminum hydroxide; surface-active substances such as lysolecithin, Pluronic Polyol, polyanion, peptide, oil emulsion, keyhole limpet hemocyanin, and dinitrophenol; and human adjuvants such as BCG (Bacille de Calmette et Guérin) and Corynebacterium parvum.
- The additive, dosage form, and content of an active ingredient (antibody of the present invention) in
Drug 2 of the present invention are the same as those inDrug 1 of the present invention. - The amount of
Drug 2 in the present invention can be determined according to the type of usage. IfDrug 2 is used for drugs, the amount can be determined by a clinical physician, taking into consideration various factors, such as the administration route, the type of disease, the degree of symptoms, patient's age, sex, and body weight, severity of disease, pharmacological findings such as pharmacokinetics and toxicological characteristics, use or non-use of a drug delivery system, and whetherDrug 2 is administered as part of a combinational drug with other medicinal agents.Drug 2 of the present invention is not particularly limited. It is preferably used so that the administration amount of the antibody of the present invention per administration is 1 μg to 10 mg/kg (body weight). The interval and frequency of administration is not particularly limited; however, the administration can be performed once to several times (e.g., twice to ten times) per day or per month. - The present invention is described in detail below with reference to Examples. However, the present invention is not limited to these Examples.
- PcrV, OprF, and Exotoxin A were selected from antigen proteins involving Pseudomonas aeruginosa virulence. As an OprF antigen, the partial polypeptide (OprF198-342) of OprF protein was used. As an Exotoxin A antigen, a partial polypeptide (mTox413-Δ578E-638) obtained by removing #578 glutamic acid, which was an enzyme active amino acid, by a genetic modification technique from the ToxA413-538 domain of the C-terminal region containing the enzyme active site of the Exotoxin A protein.
- The total of three gene regions, comprising pcrV1-882 (nucleotide sequence: SEQ ID No. 2) encoding the full-length of PcrV1-294 (amino acid sequence: SEQ ID No. 1), oprF594-1028 (nucleotide sequence: SEQ ID No. 4) encoding the intermediate domain region of OprF, OprF198-342 (amino acid sequence: SEQ ID No.3), and mTox1239-1916 (nucleotide sequence: SEQ ID No. 6) encoding the C-terminal domain of Exotoxin A, ToxA413-638 (amino acid sequence: SEQ ID No. 5) was cloned from P. aeruginosa strain PA103 chromosomal DNA. For ToxA413-638, #578 glutamic acid was removed by a genetic modification technique (amino acid sequence: SEQ ID No. 7, nucleotide sequence: SEQ ID No. 8).
- The three resulting gene regions were linked using the polymerase chain reaction technique by using linker Oligo DNA encoding glycine serine linkers (-GGGGS- (SEQ ID No.9) and -GSGGSG- (SEQ ID No.10)). DNA (nucleotide sequence: SEQ ID No.12) encoding a protein (amino acid sequence: SEQ ID No. 11) (abbreviated as “POmT”) comprising PcrV1-294, a GGGGS linker, OprF198-342, GSGGSG, and mTox413-Δ578E-638 in this order from the N-terminal side was prepared, and incorporated into a commercially available vector creation (TAGzyme (registered trademark) pQE2, QiAGen) for expression of a genetically modified E. coli protein, thus preparing a vector (TAGzyme pQE2::PomT) for generating a genetically modified three-antigen protein POmT without containing a purification tag (
FIG. 1 ). The N-terminal 6×His tag amino acid sequence for purification of protein in the vector is “MKHHHHHHHHMHHAKM (SEQ ID No.13),” and the tag portion can be decomposed by DAPase enzyme treatment after purification in an IMAC column. - The vector was introduced into E. coli, and the resulting E. coli was cultured at 30° C. for 10 hours. The E. coli was then sonicated, and the crushed material was purified in the IMAC column to obtain 6×His-tagged POmT (
FIG. 2 ). This was subjected to a DAPase enzyme treatment to decompose the tag portion, thus purifying a gene-recombinant three-antigen protein POmT. - A PcrV antigen was prepared by the same procedure as in Example 1, except that only the full-length of PcrV1-294 cloned from Pseudomonas aeruginosa strain PA103 chromosomal DNA was used as an antigen coding sequence.
- An OprF antigen was prepared by the same procedure as in Example 1, except that only OprF198-342 cloned from Pseudomonas aeruginosa strain PA103 chromosomal DNA was used as an antigen coding sequence.
- An mTox antigen was prepared by the same procedure as in Example 1, except that only mTox413-78E-638 cloned from Pseudomonas aeruginosa strain PA103 chromosomal DNA was used as an antigen coding sequence.
- The vaccine effect of the three-antigen protein POmT was evaluated using a mouse Pseudomonas aeruginosa pneumonia model. Specifically, the evaluation was performed as follows.
- The purified vaccine protein (PomT, PcrV, OprF, or mTox; 10 μg/mouse) was absorbed into Alhydrogel (aluminum hydroxide gel adjuvant), and a protein-adjuvant mixture (100 uL) was injected intramuscularly into the thigh muscle of each mouse (POmT group: n=21, PcrV group: n=11). In the control group (n=18), an adjuvant alone was injected. Four weeks later, injection was performed again. Another four weeks later, antibody titer measurement and an infection experiment were performed.
- The antibody titer measurement was performed as follows. According to enzyme-linked immunosorbent assay (ELISA), the POmT protein, PcrV1-294, OprF198-342, and mTox413-Δ578E-638 were used as antigen proteins, and the titers of antibodies binding to these antigens were quantified by the colorimetric method. The results confirmed that the anti-PcrV titer, anti-OprF titer, and anti-mTox titer were all increased in mice immunized with the three-antigen vaccine protein POmT+Alum (
FIG. 3 ). - In the infection experiment, mice were subjected to general anaesthesia with sevoflurane inhalation for a short time period (about 1 minute), and 1×106 Pseudomonas aeruginosa PA103 strains were intratracheally administered using a blunt needle. The mice were awakened after one minute and allowed to move freely in the cage. The number of survivors after 0 hours (before bacterial administration), 4 hours, 8 hours, 12 hours, and 24 hours, and the rectal temperature of the surviving mice was measured and counted as a 24-hour survival rate. The lungs of the mice were also removed after 24 hours and quantitatively homogenized to quantify edema. As a result, in mice to which a gene-recombinant antigen protein POmT containing three protein antigens had been administered, the
survival rate 24 hours after the pulmonary administration of a lethal dose of Pseudomonas aeruginosa (PA103 strain, 1×106 CFU/mouse) was significantly improved (p<0.0001) as compared to the PcrV single-administration group and the control group of the single administration with the Alhydrogen adjuvant (FIG. 4 ). Pulmonary edema was also significantly improved in the POmT administration group as compared to the two other groups (FIG. 5 ). - Sequence Listing
Claims (12)
1. A protein molecule comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.
2. The protein molecule according to claim 1 , wherein the domains are linked individually via a linker.
3. The protein molecule according to claim 1 , comprising the PcrV antigen domain, OprF antigen domain, and Exotoxin A antigen domain.
4. The protein molecule according to claim 3 , wherein the PcrV antigen domain, OprF antigen domain, and Exotoxin A antigen domain are arranged in this order.
5. The protein molecule according to claim 1 , which is a fusion protein.
6. The protein molecule according to claim 5 , wherein the number of amino acid residues is 700 or less.
7. A polynucleotide comprising a coding sequence of the protein molecule according to claim 5 .
8. A composition comprising at least one member selected from the group consisting of a PcrV antigen and a polynucleotide comprising a PcrV antigen-coding sequence, and at least one member selected from the group consisting of an OprF antigen, a polynucleotide comprising an OprF antigen-coding sequence, an Exotoxin A antigen, and a polynucleotide comprising an Exotoxin A antigen-coding sequence.
9. A drug comprising the protein molecule according to claim 1 .
10. The drug according to claim 9 , which is an anti-Pseudomonas aeruginosa vaccine.
11. A drug comprising an antibody against a PcrV antigen, and at least one member selected from the group consisting of an antibody against an OprF antigen and an antibody against an Exotoxin A antigen.
12. The drug according to claim 11 , which is for use in the treatment of Pseudomonas aeruginosa infection.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-092376 | 2020-05-27 | ||
JP2020092376 | 2020-05-27 | ||
PCT/JP2021/018141 WO2021241240A1 (en) | 2020-05-27 | 2021-05-13 | Protein molecule useful for anti-pseudomonas aeruginosa vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230241197A1 true US20230241197A1 (en) | 2023-08-03 |
Family
ID=78745099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/927,199 Pending US20230241197A1 (en) | 2020-05-27 | 2021-05-13 | Protein molecule useful for anti-pseudomonas aeruginosa vaccine |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230241197A1 (en) |
JP (1) | JPWO2021241240A1 (en) |
WO (1) | WO2021241240A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008133206A (en) * | 2006-11-28 | 2008-06-12 | Yokohama City Univ | Pharmaceutical composition capable of inducing phylactic ability against pseudomonas aeruginosa |
GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
-
2021
- 2021-05-13 US US17/927,199 patent/US20230241197A1/en active Pending
- 2021-05-13 WO PCT/JP2021/018141 patent/WO2021241240A1/en active Application Filing
- 2021-05-13 JP JP2022526872A patent/JPWO2021241240A1/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021241240A1 (en) | 2021-12-02 |
JPWO2021241240A1 (en) | 2021-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0754231B1 (en) | Peptide fragment of the respiratory syncytial virus g protein, immunogenic agent, pharmaceutical composition containing same, and preparation method | |
US9850475B2 (en) | Method for delivering agents into cells using bacterial toxins | |
US9611307B2 (en) | Method for increasing granulocyte number in a patient by administering superactive IL-33 fragments | |
KR102014502B1 (en) | Immunogenic composition | |
EA014531B1 (en) | Anti-amyloid immunogenic compositions, method and uses | |
KR20110041479A (en) | Novel immunoadjuvant flagellin-based compounds and use thereof | |
JP2008237227A (en) | Chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequence | |
WO2012026309A1 (en) | Creation of anti-pad4 antibody pharmaceutical | |
JP2023033394A (en) | Antibody fragments for treatment of biofilm-related disorders | |
WO2022202816A1 (en) | Peptide and peptide-containing composition | |
JP2022171777A (en) | Dnabii vaccine and antibody with enhanced activity | |
WO2017192594A1 (en) | Binding moieties for biofilm remediation | |
TW202222821A (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
EP2910634A1 (en) | Vaccine for preventing porcine edema disease | |
US11007248B2 (en) | Suppression of allergic lung inflammation and hyperreactivity | |
SK14832001A3 (en) | Interleukin 5 analogue, a nucleic acid fragment, a vector, a cell, compositions and use | |
WO2015143581A1 (en) | Target-specific double-mutant fusion protein and preparation process therefor | |
US20230241197A1 (en) | Protein molecule useful for anti-pseudomonas aeruginosa vaccine | |
EP0538352B1 (en) | IMMUNOGENIC PEPTIDE SEQUENCE FROM $i(ECHINOCOCCUS GRANULOSUS), DNA SEQUENCE CODING FOR SAID PEPTIDE SEQUENCE, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | |
CA2522329A1 (en) | Inhibitors of coronavirus | |
JP2013071904A (en) | Peptide having anti-influenza virus activity | |
WO2021218947A1 (en) | Anti-novel coronavirus monoclonal antibody and application thereof | |
JP2023551047A (en) | Virus-like particles and their production method | |
WO2022045251A1 (en) | Mutant ace2 protein | |
US20210008193A1 (en) | Protein antigens for vaccinating against nontypeable haemophilus influenzae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAWA, TEIJI;REEL/FRAME:061855/0904 Effective date: 20221026 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |